Arrowhead’s Plozasiran Phase 3 Win Clears Key Hurdle; sNDA Acceleration Lifts Outlook

What happened

The positive Phase 3 results for plozasiran in severe hypertriglyceridemia remove the binary risk that anchored our WAIT rating, and the accelerated sNDA timeline shaves months off the regulatory path. The master report’s bear case—slipping timelines or failed data—has been invalidated, though we must still see actual sNDA filing and REDEMPLO net-sales traction beyond the earnings call’s anecdotal growth. The company’s rare-disease launch continues to build, but the stock now discounts both the FCS ramp and post-FCS expansion, leaving little room for execution missteps. The positive data release likely pulls forward valuation, bringing the trim-above threshold of $85 into view if commercialization metrics firm up. However, with the key catalyst now behind, the risk-reward has improved, but the 15% PIK term loan and dilution overhang still warrant vigilance on cash burn and operating leverage.

Implication

With plozasiran’s sHTG Phase 3 success and an accelerated sNDA path, Arrowhead’s thesis shifts decisively from speculative to fundamental; we now assign a higher base-case probability. The company’s REDEMPLO launch for FCS is gaining traction, and the larger sHTG indication could unlock a risk-adjusted $1B sales opportunity by 2031. However, the stock has already climbed in anticipation, and the next quarter must demonstrate meaningful net-sales disclosure and payer coverage expansion. The 15% PIK term loan remains a drag on capital allocation, and dilution from the 2026 financing overhang persists. We maintain the HOLD rating but raise the trim target to $95, reflecting the derisked regulatory path, while still emphasizing that $55–$60 offers a better risk-adjusted entry.

Thesis delta

The investment thesis shifts from WAIT to HOLD with bullish bias. The positive Phase 3 outcome and sNDA acceleration resolve the major timeline risk, raising the probability of base-case $70 to bull-case $105 over the next 12 months. However, the market has steadily re-rated ARWR since the data, and an entry near current levels demands confirmation of REDEMPLO’s net-sales durability to justify the expansion narrative.